Results 281 to 290 of about 4,371,529 (377)

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon   +28 more
wiley   +1 more source

Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.

open access: yesJAMA Intern Med
Horrow C   +4 more
europepmc   +1 more source

Study on the Prescriptions of Drug Interactions in Hospitalized Patients.

open access: bronze, 1995
Kiyomi Iwai   +3 more
openalex   +2 more sources

Estimated Savings From International Reference Pricing for Prescription Drugs.

open access: yesJAMA, 2021
Mulcahy AW   +4 more
europepmc   +1 more source

Gout and NLRP3 Inflammasome Biology

open access: yesArthritis &Rheumatology, EarlyView.
This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley   +1 more source

Machine Learning Analysis of Whole‐Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Tumor necrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to non‐response or adverse effects. This study aimed to identify biomarkers predictive of adalimumab treatment
Chuan Fu Yap   +12 more
wiley   +1 more source

Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double‐blind, phase 3 trial in China

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy